A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

BACKGROUND: Decitabine was evaluated for its efficacy and safety in Korean patients with myelodysplastic syndrome with IPSS score of 0.5 or over. DESIGN AND METHODS: Decitabine 20 mg/m(2)/day was given intravenously over one hour for five consecutive days every four weeks. The primary end point was...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Lee, Je-Hwan, Jang, Jun Ho, Park, Jinny, Park, Seonyang, Joo, Young-Don, Kim, Yeo-Kyeoung, Kim, Hoon-Gu, Choi, Chul Won, Kim, Sung-Hyun, Park, Seong Kyu, Park, Eunkyung, Min, Yoo Hong
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Ferrata Storti Foundation 2011
Onderwerpen:
Original Articles
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3186304/
https://ncbi.nlm.nih.gov/pubmed/21659363
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.046078
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items